According to data presented at the Society for Investigative Dermatology annual meeting, MiRagen Therapeutics’ MRG-201 has reversed fibrosis in mice with pulmonary fibrosis, reports.

MRG-201 targets microRNAs, small molecules that control whether genes are switched on or off. The results come from preclinical trial studies and ongoing Phase 1 trial of MRG-201.

MicroRNAs, also known as miRNAs, have attracted a lot research attention in recent years. Because they control genes’ on and off switches, they are involved in many disease processes. That has prompted researchers to develop treatments that target them. Researchers believe microRNAs can be controlled to harness diseases such as lung fibrosis, or scarring.